miR-34a is a tumor supressor lowly expressed in triple negative breast cancer, and miR-34a replacement therapy has been suggested for patients with this disease. In this project we confirm that miR-34a is highly associated with regulation of the cell cycle, and we show that miR-34a expression is also associated with altered production of amino acids.
Multi-modal meta-analysis of cancer cell line omics profiles identifies ECHDC1 as a novel breast tumor suppressor
Mol Syst Biol, 17 (3), e9526
Epigenome-wide gene-age interaction analysis reveals reversed effects of PRODH DNA methylation on survival between young and elderly early-stage NSCLC patients
Aging (Albany NY), 12 (11), 10642-10662
Independent Validation of Early-Stage Non-Small Cell Lung Cancer Prognostic Scores Incorporating Epigenetic and Transcriptional Biomarkers With Gene-Gene Interactions and Main Effects
Chest, 158 (2), 808-819